Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective
International Journal of Chronic Obstructive Pulmonary Disease · 2025
DOI: 10.2147/copd.s492524 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Kai-Michael Beeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Insaf Respiratory Research Institute, Taunusstein, Germany. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Chlorobenzenes, Bronchodilator Agents, Benzyl Alcohols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: GSK.
Themen: COPD
Abstract (Originalsprache)
Purpose
The INTREPID trial showed that once-daily single-inhaler triple therapy (SITT) using fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) offers clinical benefits versus non-ELLIPTA multiple-inhaler triple therapy (MITT) for the management of chronic obstructive pulmonary disease (COPD) in real-world clinical practice. This analysis evaluated the cost-effectiveness of SITT with FF/UMEC/VI versus non-ELLIPTA MITT for treating symptomatic COPD from a German healthcare perspective. Patients and Methods: Data from the INTREPID trial, including baseline characteristics, treatment effects (forced expiratory volume in 1 second and St. George's Respiratory Questionnaire score [derived from exploratory COPD assessment test score mapping]), and discontinuation rates, along with German healthcare resource and drug costs (2023 Euros), were used to populate the GALAXY COPD model. The analysis was conducted over a lifetime horizon, with outcomes including life years (LYs), quality-adjusted LYs (QALYs), and incremental cost-utility ratios. The robustness of the analysis was assessed using scenario, one-way sensitivity, and probabilistic analyses.
Results
Improved lifetime outcomes were predicted for FF/UMEC/VI versus non-ELLIPTA MITT, providing additional LYs of 0.174 (95% range: 0.065, 0.322) and QALYs of 0.261 (0.186, 0.346) per patient, together with cost savings of €2,850 (€3,517, €2,220). Additionally, patients receiving FF/UMEC/VI were predicted to experience a reduction in exacerbations (-0.063), highlighting its dominance as the preferred treatment option. These findings remained consistent across one-way sensitivity, scenario, and probabilistic analyses, highlighting the robustness of FF/UMEC/VI as a cost-effective solution for COPD management in Germany.
Conclusion
FF/UMEC/VI offers clinical benefits and cost savings compared with non-ELLIPTA MITT, suggesting that it may reduce the burden of COPD in Germany and warranting consideration as a preferred treatment option by physicians.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Insaf Respiratory Research Institute, Taunusstein, Germany.
- Global Medical Affairs, GSK, Munich, Germany.
- Insights, Evidence and Value - Health Economics & Epidemiology, ICON Plc, NJ, USA.
- Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK.
- ICON Health Economics, ICON Plc, Vancouver, Canada.
- Insights, Evidence and Value - Health Economics & Epidemiology, ICON Plc, Houston, TX, USA.
ORCID-Profile: Kai-Michael Beeh, Jing Claussen, Alan Martin, Robyn Kendall, Afisi S Ismaila
Förderung
- GSK
Zitieren
APA
Beeh, K. M., Claussen, J., Shah, D., Martin, A., Kendall, R., Dasari, P., Ismaila, A. S., & Noorduyn, S. G. (2025). Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s492524
Vancouver
Beeh KM, Claussen J, Shah D, Martin A, Kendall R, Dasari P, et al. Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s492524
BibTeX
@article{Beeh2025,
author = {Beeh, Kai-Michael and Claussen, Jing and Shah, Dhvani and Martin, Alan and Kendall, Robyn and Dasari, Priyadarsini and Ismaila, Afisi S and Noorduyn, Stephen G},
title = {Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2025},
doi = {10.2147/copd.s492524}
}
EUVIMED